Kuros Biosciences's total assets for Q2 2024 were CHF77.30M, an increase of 1.84% from the previous quarter. CH:KURN total liabilities were CHF17.13M for the fiscal quarter, a -10.76% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.